1 – 10 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3
(
- Contribution to journal › Article
-
Mark
AlphaML : A clear, legible, explainable, transparent, and elucidative binary classification platform for tabular data
(
- Contribution to journal › Article
- 2023
-
Mark
Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD
(
- Contribution to journal › Article
-
Mark
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
(
- Contribution to journal › Article
- 2022
-
Mark
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
(
- Contribution to journal › Article
- 2020
-
Mark
Why and how to investigate the role of protein phosphorylation in ZIP and ZnT zinc transporter activity and regulation
(
- Contribution to journal › Scientific review
- 2019
-
Mark
The role of SRC family kinases in FLT3 signaling
(
- Contribution to journal › Scientific review
-
Mark
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
(
- Contribution to journal › Letter
- 2018
-
Mark
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
(
- Contribution to journal › Article
-
Mark
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia
(
- Contribution to journal › Article